BACKGROUND: Salmonella causes an estimated 100 000 antimicrobial-resistant infections annually in the United States. Salmonella antimicrobial resistance may result in bacteremia and poor outcomes. We describe antimicrobial resistance among nontyphoidal Salmonella blood isolates, using data from the National Antimicrobial Resistance Monitoring System. METHODS: Human nontyphoidal Salmonella isolates from 2003 to 2013 were classified as fully susceptible, resistant to ≥1 antimicrobial agent, or resistant to a first-line agent. Logistic regression was used to compare resistance patterns, serotypes, and patient characteristics for Salmonella isolated from blood versus stool and to determine resistance trends over time. RESULTS: Approximately 20% of blood isolates had antimicrobial resistance to a first-line treatment agent. Bacteremia was associated with male sex, age ≥65 years, and specific serotypes. Blood isolates were more likely to be resistant to ≥1 agent for serotypes Enteritidis, Javiana, Panama, and Typhimurium. Blood isolates were most commonly resistant to tetracycline (19%), and more likely resistant to a first-line agent (odds ratio, 1.81; 95% confidence interval, 1.56-2.11) than stool isolates. Ceftriaxone resistance increased in blood isolates from 2003 to 2013 (odd ratio, 1.12; 95% confidence interval, 1.02-1.22). CONCLUSIONS: Resistance to first-line treatment agents in patients with Salmonella bacteremia is a concern for public health and for informing clinical decisions. Judicious antimicrobial use is crucial to limit resistance. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Salmonella causes an estimated 100 000 antimicrobial-resistant infections annually in the United States. Salmonella antimicrobial resistance may result in bacteremia and poor outcomes. We describe antimicrobial resistance among nontyphoidal Salmonella blood isolates, using data from the National Antimicrobial Resistance Monitoring System. METHODS:Humannontyphoidal Salmonella isolates from 2003 to 2013 were classified as fully susceptible, resistant to ≥1 antimicrobial agent, or resistant to a first-line agent. Logistic regression was used to compare resistance patterns, serotypes, and patient characteristics for Salmonella isolated from blood versus stool and to determine resistance trends over time. RESULTS: Approximately 20% of blood isolates had antimicrobial resistance to a first-line treatment agent. Bacteremia was associated with male sex, age ≥65 years, and specific serotypes. Blood isolates were more likely to be resistant to ≥1 agent for serotypes Enteritidis, Javiana, Panama, and Typhimurium. Blood isolates were most commonly resistant to tetracycline (19%), and more likely resistant to a first-line agent (odds ratio, 1.81; 95% confidence interval, 1.56-2.11) than stool isolates. Ceftriaxone resistance increased in blood isolates from 2003 to 2013 (odd ratio, 1.12; 95% confidence interval, 1.02-1.22). CONCLUSIONS: Resistance to first-line treatment agents in patients with Salmonella bacteremia is a concern for public health and for informing clinical decisions. Judicious antimicrobial use is crucial to limit resistance. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Yuliana K Bosken; Rizi Ai; Eduardo Hilario; Rittik K Ghosh; Michael F Dunn; Shih-Hsin Kan; Dimitri Niks; Huanbin Zhou; Wenbo Ma; Leonard J Mueller; Li Fan; Chia-En A Chang Journal: Protein Sci Date: 2021-11-26 Impact factor: 6.725
Authors: Shannon Katiyo; Berit Muller-Pebody; Mehdi Minaji; David Powell; Alan P Johnson; Elizabeth De Pinna; Martin Day; Ross Harris; Gauri Godbole Journal: J Clin Microbiol Date: 2019-01-02 Impact factor: 5.948
Authors: Felicita Medalla; Weidong Gu; Cindy R Friedman; Michael Judd; Jason Folster; Patricia M Griffin; Robert M Hoekstra Journal: Emerg Infect Dis Date: 2021-06 Impact factor: 6.883
Authors: Deborah A Williamson; Courtney R Lane; Marion Easton; Mary Valcanis; Janet Strachan; Mark G Veitch; Martyn D Kirk; Benjamin P Howden Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191
Authors: Kelly E Davidson; Barbara A Byrne; Alda F A Pires; K Gary Magdesian; Richard V Pereira Journal: PLoS One Date: 2018-06-28 Impact factor: 3.240